Serotherapy and Bone Marrow Transplantation
Within the human hematopoietic system, monoclonal antibodies have been used to identify a large number of surface antigens expressed by both normal and malignant cells, and in many instances it has now been possible to ascribe specific functions to individual cell surface molecules. Since monoclonal antibodies can be produced in large quantities and can be easily purified, it has also been possible to explore the potential therapeutic applications of these unique reagents. As a result, several different antibodies have been used in serotherapy trials in patients with refractory leukemia or lymphoma1–5 and in several solid tumors.6 In each of these studies, antibodies have been infused, with the hopes that antibody-bound tumor cells would subsequently be eliminated by natural effector mechanisms. In addition, monoclonal antibodies have also been utilized under more controlled circumstances in vitro in order to deplete specific target cells from bone marrow prior to either autologous7 or allogeneic marrow transplantation.8 In order to demonstrate the potential utility of these reagents, this chapter will focus on the specific clinical applications of monoclonal antibodies in patients with acute lymphoblastic leukemia (ALL). Although other clinical situations and other monoclonal antibodies with different specificity will undoubtedly present unique problems, much of the information gained in patients with ALL will be applicable to other leukemias and lymphomas and, to a lesser extent, to solid tumors as well.
KeywordsToxicity Catheter Lymphoma Leukemia Adenocarcinoma
Unable to display preview. Download preview PDF.
- 6.Sears, H. F., Herlyn, D., Steplewski, Z., and Koprowski, H., 1984, Effects of monoclonal antibody immunotherapy on patients with gastrointestinal adenocarcinoma, J. Biol. Resp. Modif. 3:138–150.Google Scholar
- 7.Ritz, J., Sallan, S. E., Bast, R. C., Lipton, J. M., Clavell, L. A., Feeney, M., Hercend, T., Nathan, D. C., and Schlossman, S. F., 1982, Autologous bone marrow transplantation in CALLA positive acute lymphoblastic leukemias after in vitro treatment with J5 monoclonal antibody and complement, Lancet ii:60–63.CrossRefGoogle Scholar
- 8.Reinherz, E. L., Geha, C., Rappeport, J. M., Wilson, M., Penta, A. C., Hussey, R. E., Fitzgerald, K. A., Daley, J., Levine, H., Rosen, F. S., and Schlossman, S. F., 1982, Immune reconstitution in severe combined immunodeficiency following transplantation with T lymphocyte depleted HLA haplotype mismatched bone marrow, Proc. Natl. Acad. Sci. USA 79:6047–6051.PubMedCrossRefGoogle Scholar
- 13.Hokland, P., Rosenthal, P., Griffin, J. D., Nadler, L. M., Daley, J. F., Hokland, M., Schlossman, S. F., and Ritz, J., 1983, Purification and characterization of fetal hematopoietic cells which express the common acute lymphoblastic leukemia antigen (CALLA), J. Exp. Med. 157:114–129.PubMedCrossRefGoogle Scholar
- 20.Komada, Y., Peiper, S. C., Melvin, S. L., Metzgar, D. W., Tarnowski, B. H., and Green, A. A., 1983, A monoclonal antibody (SJ-9A4) to p24 present on common ALLs, neuroblastomas and platelets. I. Characterization and development of a unique radioimmunometric assay, Leukemia Res. 7:487–498.CrossRefGoogle Scholar
- 26.Nadler, L. M., Takvorian, T., Botnick, L., Bast, R. C., Finberg, R., Hellman, S., Canellos, G. P., and Schlossman, S. F., 1984, Anti-B1 monoclonal antibody and complement treated autologous bone marrow transplantation for relapsed B cell non-Hodgkin’s lymphoma, Lancet ii:427–434.CrossRefGoogle Scholar
- 28.Philips, G. L., Herzig, R. H., Lazarus, H. M., Fay, J. W., Wolff, S. N., Mill, W. B., Lin, H., Thomas, P. R. M., Glasgow, G. P., Shina, D. C., and Herzig, G. P., 1984, Treatment of resistant malignant lymphoma with cyclophosphamide, total body irradiation, and transplantation of cryopreserved autologous marrow, N. Engl. J. Med. 310:1557–1561.CrossRefGoogle Scholar